Literature DB >> 30543391

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Srinivasa P S Rao1, Michael P Barrett2, Glenn Dranoff3, Christopher J Faraday4, Claudio R Gimpelewicz5, Asrat Hailu6, Catherine L Jones1, John M Kelly7, Janis K Lazdins-Helds8, Pascal Mäser9, Jose Mengel10,11, Jeremy C Mottram12, Charles E Mowbray13, David L Sacks14, Phillip Scott15, Gerald F Späth16, Rick L Tarleton17, Jonathan M Spector1, Thierry T Diagana1.   

Abstract

Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30543391     DOI: 10.1021/acsinfecdis.8b00298

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  21 in total

1.  Targeted protein degradation using deGradFP in Trypanosoma brucei.

Authors:  Midori Ishii; Bungo Akiyoshi
Journal:  Wellcome Open Res       Date:  2022-06-23

2.  Diaryl Ureas as an Antiprotozoal Chemotype.

Authors:  Derek A Leas; Austin G Sanford; Jianbo Wu; Monica Cal; Marcel Kaiser; Sergio Wittlin; Ryan M Hemsley; Elyssa B Darner; LeeAnna M Lui; Paul H Davis; Jonathan L Vennerstrom
Journal:  ACS Infect Dis       Date:  2021-05-10       Impact factor: 5.578

Review 3.  Experimental Strategies to Explore Drug Action and Resistance in Kinetoplastid Parasites.

Authors:  Magali Van den Kerkhof; Yann G-J Sterckx; Philippe Leprohon; Louis Maes; Guy Caljon
Journal:  Microorganisms       Date:  2020-06-24

Review 4.  The Strong Anti-Kinetoplastid Properties of Bee Propolis: Composition and Identification of the Active Agents and Their Biochemical Targets.

Authors:  Godwin U Ebiloma; Nahandoo Ichoron; Weam Siheri; David G Watson; John O Igoli; Harry P De Koning
Journal:  Molecules       Date:  2020-11-05       Impact factor: 4.411

5.  Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.

Authors:  Brima M Younis; Mohamed Osman; Eltahir A G Khalil; Francesco Santoro; Simone Furini; Rebecca Wiggins; Ada Keding; Monica Carraro; Anas E A Musa; Mujahid A A Abdarahaman; Laura Mandefield; Martin Bland; Toni Aebischer; Rhian Gabe; Alison M Layton; Charles J N Lacey; Paul M Kaye; Ahmed M Musa
Journal:  Mol Ther       Date:  2021-03-27       Impact factor: 11.454

Review 6.  New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story.

Authors:  Emily A Dickie; Federica Giordani; Matthew K Gould; Pascal Mäser; Christian Burri; Jeremy C Mottram; Srinivasa P S Rao; Michael P Barrett
Journal:  Trop Med Infect Dis       Date:  2020-02-19

7.  Withanolides from Withania aristata as Antikinetoplastid Agents through Induction of Programmed Cell Death.

Authors:  Atteneri López-Arencibia; Desirée San Nicolás-Hernández; Carlos J Bethencourt-Estrella; Ines Sifaoui; María Reyes-Batlle; Rubén L Rodríguez-Expósito; Aitor Rizo-Liendo; Jacob Lorenzo-Morales; Isabel L Bazzocchi; José E Piñero; Ignacio A Jiménez
Journal:  Pathogens       Date:  2019-10-01

8.  A Comprehensive QSAR Study on Antileishmanial and Antitrypanosomal Cinnamate Ester Analogues.

Authors:  Freddy A Bernal; Thomas J Schmidt
Journal:  Molecules       Date:  2019-11-28       Impact factor: 4.411

9.  Synthesis and evaluation of novel 2,4-disubstituted arylthiazoles against T. brucei.

Authors:  Markos-Orestis Georgiadis; Violeta Kourbeli; Ioannis P Papanastasiou; Andrew Tsotinis; Martin C Taylor; John M Kelly
Journal:  RSC Med Chem       Date:  2019-12-19

10.  A Trypanosoma brucei ORFeome-Based Gain-of-Function Library Identifies Genes That Promote Survival during Melarsoprol Treatment.

Authors:  McKenzie Carter; Stephanie Gomez; Sam Gritz; Stephen Larson; Eugenia Silva-Herzog; Hee-Sook Kim; Danae Schulz; Galadriel Hovel-Miner
Journal:  mSphere       Date:  2020-10-07       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.